.png)
Agenzia Italiana del Farmaco
home
Highlights
-
15 Apr 2025
Press releases
AIFA-Regions working group: shared calculation method for the class economic impact of glyphozines
This was a fruitful meeting, as it was decided to share the calculation method to assess the economic impact of the class change for this category of drugs.
-
17 Apr 2025
Publications
"Horizon Scanning: scenario dei medicinali in arrivo”. AIFA pubblica il Rapporto 2025
Il Rapporto Horizon Scanning ha lo scopo di fornire informazioni sui nuovi medicinali e sulle nuove indicazioni che hanno ricevuto un parere positivo dell’Agenzia Europea per i Medicinali (EMA) nel 2024 o che potrebbero riceverlo nell’anno in corso.
-
30 Apr 2025
Press releases
Pharmaceutical expenditure for direct purchases by the Regions slows in the last months of the year but it exceeds the 2024 ‘ceiling’ by 3.6 billion
Considering that several medicines shifted from the innovative fund to the direct purchases one, the trend is in line with previous years. For the NHS approved care regime there was a surplus of 651 million.
-
23 Apr 2025
Press releases
AIFA’s top management on an institutional mission to London
President Nisticò: “We are laying the foundations for greater collaboration on clinical research, access to innovation and drug safety”.
-
15 Apr 2025
Press releases
AIFA-Regions working group: shared calculation method for the class economic impact of glyphozines
This was a fruitful meeting, as it was decided to share the calculation method to assess the economic impact of the class change for this category of drugs.
-
17 Apr 2025
Publications
"Horizon Scanning: scenario dei medicinali in arrivo”. AIFA pubblica il Rapporto 2025
Il Rapporto Horizon Scanning ha lo scopo di fornire informazioni sui nuovi medicinali e sulle nuove indicazioni che hanno ricevuto un parere positivo dell’Agenzia Europea per i Medicinali (EMA) nel 2024 o che potrebbero riceverlo nell’anno in corso.
-
30 Apr 2025
Press releases
Pharmaceutical expenditure for direct purchases by the Regions slows in the last months of the year but it exceeds the 2024 ‘ceiling’ by 3.6 billion
Considering that several medicines shifted from the innovative fund to the direct purchases one, the trend is in line with previous years. For the NHS approved care regime there was a surplus of 651 million.
-
23 Apr 2025
Press releases
AIFA’s top management on an institutional mission to London
President Nisticò: “We are laying the foundations for greater collaboration on clinical research, access to innovation and drug safety”.
News
09 May 2025
Information and communication
EU regulators agree workplan to optimise use of data and artificial intelligence (AI)
08 May 2025
Safety of medicinal products
Measures to minimise risk of suicidal thoughts with finasteride and dutasteride medicines
06 May 2025
Innovative medicinal products
Innovative medicines list: AIFA publishes April 2025 update
30 Apr 2025
Monitoring pharmaceutical expenditure
Biosimilar medicines in Italy: AIFA reports updated
24 Apr 2025
Quality and Inspections
Direct communication with healthcare professionals on Opzelura (ruxolitinib)
18 Apr 2025
Consumption and pharmaceutical expenditure
Procedure for the review and validation of lists of therapeutic indications for innovative medicines by pharmaceutical companies
FarmaciLine
Questions regarding drug efficacy, safety and availability
TOLL-FREE NUMBER
Services
Interactive OsMed - The use of medicines in Italy
An interactive consultation of data on the use of medicines in Italy in the general and regional population, described in terms of expenditure, volumes, typology
